Spotlight Shines on CPA in Latest House Ways & Means Trade Hearing
At a recent House Ways & Means subcommittee hearing on trade, CEO Michael Stumo talks de minimis, and the inescapable realities of China’s forced labor.
Written Testimony Before the House Ways & Means Subcommittee on Trade: Modernizing Customs Policies to Protect American Workers and Secure Supply Chains
The following written testimony was submitted by Michael Stumo, CEO of CPA, to the House Ways and Means Subcommittee on Trade for a hearing titled,
House Committee Holds Hearing on Drug Shortages
The U.S. is increasingly reliant on imported drugs from uninspected labs. It’s not safe. What can be done about it?
Written Testimony to the CECC: Implementation of the Uyghur Forced Labor Prevention Act and the Impact on Global Supply Chains
The following written testimony was submitted to the Congressional-Executive Commission China (CECC) on April 18, 2023 by CPA’s Robby Stephany Saunders, Vice President for National
Drug Shortages: Why They Happen, What Can Be Done About Them?
A Senate hearing on pharmaceutical shortages discusses America’s dependence on India and China, and what can be done to reshore.
Why Medicine Costs So Much Money, Despite Imports from Low-Cost Nations
The Senate Commerce Committee takes the little known, and even less understood, Pharmacy Benefit Manager industry to task for high drug costs.
After China Balloon Incident, House Financial Services Talks Risks To US
What are the risks China poses to the U.S. industrial supply chain and what can be done about it? Some quotes from Congress and witnesses from a Feb. 7 hearing.
Pharmaceuticals Are Heavily Outsourced. Can the U.S. Make More of it Here?
The U.S. is increasingly dependent on imports for drugs. One reason: a tax avoidance scheme that pits U.S. manufacturing up against Europe. What can be done about this problem?
European Pharma Considers Reshoring from India, China. Where’s the US?
The Covid-19 pandemic gave big pharma big payday. But it also caused the industry to rethink a globalized supply chain centered on Asia. What will it take to reshore at least some generic drugs to the U.S.
Supply Chain Dependence Makes Reshoring Harder – McKinsey
Can the U.S. really bring manufacturing home? A McKinsey study shows that existing concentration of some supply chains will make it hard. Here’s what needs to be done.
